Comment
doi: 10.1182/blood-2016-02-694943.
Long-awaited news for hepatic veno-occlusive disease
Affiliations
- PMID: 27034420
- DOI: 10.1182/blood-2016-02-694943
Item in Clipboard
Comment
Long-awaited news for hepatic veno-occlusive disease
Blood.
.
Free article
Abstract
In this issue of Blood, Palomo et al provide new insight into the mechanism of action of defibrotide as an endothelial protective agent, while Richardson et al present the encouraging final results of the phase 3 clinical study of defibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement in day +100 survival after hematopoietic cell transplantation (HCT) compared with historical control.
Comment on
-
What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance.Blood. 2016 Mar 31;127(13):1719-27. doi: 10.1182/blood-2015-10-676114. Epub 2016 Jan 11. Blood. 2016. PMID: 26755708 Free PMC article.
-
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29. Blood. 2016. PMID: 26825712 Free PMC article. Clinical Trial.
Similar articles
-
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.Biol Blood Marrow Transplant. 2010 Jul;16(7):1005-17. doi: 10.1016/j.bbmt.2010.02.009. Epub 2010 Feb 16. Biol Blood Marrow Transplant. 2010. PMID: 20167278 Free PMC article. Clinical Trial.
-
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29. Blood. 2016. PMID: 26825712 Free PMC article. Clinical Trial.
-
Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.Expert Rev Gastroenterol Hepatol. 2017 Oct;11(10):885-898. doi: 10.1080/17474124.2017.1370372. Epub 2017 Sep 4. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28825848
-
Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.Expert Rev Clin Pharmacol. 2018 Feb;11(2):113-124. doi: 10.1080/17512433.2018.1421943. Epub 2018 Jan 5. Expert Rev Clin Pharmacol. 2018. PMID: 29301447 Review.
-
Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.Clin Drug Investig. 2014 Dec;34(12):895-904. doi: 10.1007/s40261-014-0242-x. Clin Drug Investig. 2014. PMID: 25351934 Review.
Cited by
-
Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis.Cardiovasc Intervent Radiol. 2023 Jul;46(7):931-942. doi: 10.1007/s00270-023-03451-9. Epub 2023 May 24. Cardiovasc Intervent Radiol. 2023. PMID: 37225971
-
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant.Bone Marrow Transplant. 2022 Jul;57(7):1095-1100. doi: 10.1038/s41409-022-01689-4. Epub 2022 Apr 27. Bone Marrow Transplant. 2022. PMID: 35477992 Free PMC article.
-
Defibrotide in the treatment of hepatic veno-occlusive disease.Hepat Med. 2016 Oct 31;8:105-113. doi: 10.2147/HMER.S79243. eCollection 2016. Hepat Med. 2016. PMID: 27843363 Free PMC article. Review.
-
Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.BMC Gastroenterol. 2021 Jan 10;21(1):26. doi: 10.1186/s12876-021-01599-7. BMC Gastroenterol. 2021. PMID: 33423668 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
